IMP321 is the first clinically studied LAG3-targeting molecule and the only one currently being investigated in hepatitis B. In a study with HBsAg-positive participants, those treated with IMP321 exhibited a faster emergence of anti-HBs and a significant rise in CD4+ or CD8+ antigen-specific T cells compared to controls [55]. This evidence concerns the gene CD8A and hepatitis B virus infection.